Sogen Data · Datasets · 数据专题

胰腺癌复发轴数据集锦

单细胞 · bulk 转录组

本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。

人源单细胞

Human · Single-cell

  1. 01 GSE253429 对21例胰腺导管腺癌(PDAC)原发肿瘤样本进行单核RNA测序,其中8例来自肝转移复发患者(LIV-MR)和13例来自肺转移复发患者(LUN-MR),比较两组肿瘤细胞的转录程序差异。同时对部分样本进行低通量全基因组测序,分析其基因组特征。研究对象为人类胰腺组织,样本包含治疗前(新辅助治疗未接受)和接受新辅助治疗的个体,但分组依据为复发部位而非治疗状态。 人源 · 21 例 · GPL24676 · 2025/07/16

    设计对21例胰腺导管腺癌(PDAC)原发肿瘤样本进行单核RNA测序,其中8例来自肝转移复发患者(LIV-MR)和13例来自肺转移复发患者(LUN-MR),比较两组肿瘤细胞的转录程序差异。同时对部分样本进行低通量全基因组测序,分析其基因组特征。研究对象为人类胰腺组织,样本包含治疗前(新辅助治疗未接受)和接受新辅助治疗的个体,但分组依据为复发部位而非治疗状态。

    摘要Some patients with localized pancreatic ductal adenocarcinoma (PDAC) undergo resection with curative intent, but most experience disease recurrence and succumb to their disease. Through examination of 743 PDAC patients in a single-center we find that the site of first recurrence is a major predictor of survival. Patients with initial liver-metastatic recurrence (LIV-MR, n = 100) had significantly shorter disease-free and overall survival compared to those with initial recurrence to the lung (LUN-MR, n = 31). We performed single-nucleus RNA-seq (snRNA-seq) and low-pass whole-genome sequencing (lpWGS) on a representative population of this cohort, including 21 primary PDACs with either LIV-MR or LUN-MR, and found that malignant cells adopt transcriptional programs that mimicked that of their ultimate metastatic target organ. We validated the LIV-MR and LUN-MR signatures in multiple data sets, including single-cell RNA-seq of normal human adult and fetal liver and lung tissues, bulk, single-cell, and spatial transcriptomics of PDAC lung and liver metastases, and in vivo data modelling metastatic organotropism in PDAC and other lineages. We reconstructed two different trajectories of malignant transformation in PDAC and find that the LIV-MR and LUN-MR are associated with these, suggesting that subsequent metastatic organotropism may be determined early in tumorigenesis. Furthermore, primary PDAC tumors recurring with LIV-MR compared to LUN-MR were deplete of infiltrating T cells and enriched with M2-like macrophages, highlighting potential contributions to subsequent outcomes. Taken together, this work provides evidence for pre-existing cellular adaptations that determine metastatic organotropism and may be useful for prognostication and development of therapeutic strategies at the time of diagnosis of resectable PDAC.

  2. 02 GSE276061 对胰腺癌复发患者来源的腹水液 T 细胞及复发肿瘤浸润性 T 细胞(TILs)进行单细胞 RNA 测序,其中患者 T 细胞分别在 CAR T 输注后 7 天和 26 天采集,TILs 来自三只接受人类 CAR T 治疗的肿瘤小鼠,包含两个 SOX4 敲除重复样本和一个野生型(WT)对照样本,比较不同时间点患者 T 细胞转录组特征及 SOX4 敲除与 WT 对照组 TILs 的基因表达差异。 人源 · 5 例 · GPL18573 · 2025/07/07

    设计对胰腺癌复发患者来源的腹水液 T 细胞及复发肿瘤浸润性 T 细胞(TILs)进行单细胞 RNA 测序,其中患者 T 细胞分别在 CAR T 输注后 7 天和 26 天采集,TILs 来自三只接受人类 CAR T 治疗的肿瘤小鼠,包含两个 SOX4 敲除重复样本和一个野生型(WT)对照样本,比较不同时间点患者 T 细胞转录组特征及 SOX4 敲除与 WT 对照组 TILs 的基因表达差异。

    摘要Patients with advanced pancreatic ductal adenocarcinoma (PDAC) have a median survival time of less than a year, highlighting the urgent need for treatment advancements. We conducted a phase 1 clinical trial assessing the safety and feasibility of intravenous and local administration of anti-mesothelin CAR T cells in patients with unresectable or metastatic PDAC. Though therapy was well tolerated, limited clinical efficacy was observed. Analyses of patient samples provide insights into mechanisms of treatment resistance. Using single-cell genomic approaches, we found that CAR T cells post-infusion express exhaustion signatures, including previously identified transcription factors ID3 and SOX4, and display enrichment for Treg and GZMK+ phenotypes. Single knockout of ID3 or SOX4 appeared to enhance efficacy in xenograft models, but eventually failed, whereas double-knockout ID3 and SOX4 CAR T cells exhibit prolonged relapse-free survival, demonstrating sustained therapeutic effect and a potential avenue for engineering a more potent CAR T cell in pancreatic cancer.

人源bulk 转录组

Human · Bulk RNA-seq

  1. 01 GSE124232 对胰腺癌原发肿瘤的EpCAM+和EpCAM-亚群分别进行ATAC-seq和ribodepleted RNA-Seq分析,比较其染色质可及性及基因表达差异。 人源 · 225 例 · GPL11154 · 2021/03/31

    设计对胰腺癌原发肿瘤的EpCAM+和EpCAM-亚群分别进行ATAC-seq和ribodepleted RNA-Seq分析,比较其染色质可及性及基因表达差异。

    摘要This SuperSeries is composed of the SubSeries listed below.

  2. 02 GSE124231 对54例胰腺导管腺癌(PDAC)原发肿瘤样本中的EpCAM+恶性细胞进行ATAC-seq测序,分析染色质可及性差异以区分复发(DFS<1年)与非复发(DFS>1年)病例。随后对其中40例患者的组织微阵列(TMA)进行HNF1b和ZKSCAN1核定位的免疫组化及免疫荧光检测,比较复发与非复发病例的差异。同时使用RNA-Seq检测ribodepleted RNA。 人源 · 48 例 · GPL11154 · 2021/03/31

    设计对54例胰腺导管腺癌(PDAC)原发肿瘤样本中的EpCAM+恶性细胞进行ATAC-seq测序,分析染色质可及性差异以区分复发(DFS<1年)与非复发(DFS>1年)病例。随后对其中40例患者的组织微阵列(TMA)进行HNF1b和ZKSCAN1核定位的免疫组化及免疫荧光检测,比较复发与非复发病例的差异。同时使用RNA-Seq检测ribodepleted RNA。

    摘要About 50% of resected pancreatic ductal adenocarcinoma (PDAC) recur within just one year following surgery. Prognostic molecular markers predicting rapid recurrence are currently unavailable. We hypothesized that epigenetic differences at the level of chromatin accessibility, potentially linked to distinct differentiation states, might distinguish rapidly recurrent from non-recurrent tumors. Therefore, we interrogated genome-wide chromatin accessibility using Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq) on EpCAM+ PDAC malignant cells sorted from a cohort of 54 treatment-naïve resected tumors, in hopes of defining a tumor-intrinsic chromatin signature associated with recurrence. We discovered a signature of ~1000 loci that were differentially accessible between recurrent (disease free survival (DFS) < 1 year) and non-recurrent patients (DFS > 1 year). Through transcription factor (TF) binding motif analysis using supervised learning, we identified candidate TFs whose accessible motifs were differentially associated with recurrence. Nuclear localization of two such TFs as selected by top hits, ZKSCAN1 and HNF1b, were assessed by both immunohistochemistry and immunofluorescence on the tissue microarrays (TMA) of 40 out of 54 patients. Nuclear staining of HNF1b was strong in the non-recurrent and weak or absent in the recurrent patients but ZKSCAN1 was not significantly associated with recurrence. In an independent TMA of PDAC cohort (n=97) preselected for 52 long (OS 6 years)- and 45 short (OS 6 months)- term survivors, the number of nuclear positive cells for HNF1b was 52-fold higher in the long-term compared to the short-term survivors and that for ZKSCAN1 was 5.3-fold higher in the short-term compared to the long-term survivors. Altogether, these results provide novel prognostic molecular markers of early recurrence in PDAC and also suggest that the global epigenetic landscape is a prognostic feature in this disease.

微信二维码

课题合作 · 扫码加微信

bioinformaticsboy